according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1847031-00016 Date of first issue: 25.07.2017 4.0

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Gentamicin (8%) Injection Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone +1-551-430-6000

E-mail address of person

responsible for the SDS

EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A H360D: May damage the unborn child.

Specific target organ toxicity - repeated H373: May cause damage to organs through pro-

exposure, Category 2

Short-term (acute) aquatic hazard, Cate-

Long-term (chronic) aquatic hazard, Cat-

egory 2

longed or repeated exposure.

H400: Very toxic to aquatic life.

H411: Toxic to aquatic life with long lasting effects.

## 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word Danger

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

Hazard statements : H360D May damage the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Gentamicin

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

## Components

| Chemical name | CAS-No.             | Classification      | Concentration |
|---------------|---------------------|---------------------|---------------|
|               | EC-No.              |                     | (% w/w)       |
|               | Index-No.           |                     |               |
|               | Registration number |                     |               |
| Gentamicin    | 1403-66-3           | Repr. 1A; H360D     | 8             |
| ll .          | 215-765-8           | STOT RE 1; H372     |               |
| ll .          |                     | (Kidney, inner ear) |               |
| ll .          |                     | Aquatic Acute 1;    |               |
|               |                     | H400                |               |
|               |                     | Aquatic Chronic 1;  |               |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
|---------|----------------|---------------|---------------------------------|
| 4.0     | 06.04.2024     | 1847031-00016 | Date of first issue: 25.07.2017 |

| II             |                                       | H410  |     |
|----------------|---------------------------------------|---|-----|
|                |                                       | M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 1 |     |
| Benzyl alcohol | 100-51-6<br>202-859-9<br>603-057-00-5 | Acute Tox. 4; H302 Acute Tox. 4; H332 Eye Irrit. 2; H319 Acute toxicity esti- | 1,5 |
|                |                                       | Mate Acute oral toxicity: 1.620 mg/kg   |     |

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

## 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child.

May cause damage to organs through prolonged or repeated

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1847031-00016 Date of first issue: 25.07.2017 4.0

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

## **SECTION 5: Firefighting measures**

5.1 Extinguishing media

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

**Environmental precautions** Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

## **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

| Components | CAS-No.                  | Value type (Form | Control parameters | Basis    |
|------------|--------------------------|------------------|--------------------|----------|
|            |                          | of exposure)     |                    |          |
| Gentamicin | 1403-66-3                | TWA              | 0.1 mg/m3 (OEB 2)  | Internal |
|            | Further information: OTO |                  |                    |          |

## Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

| Substance name | End Use   | Exposure routes | Potential health effects   | Value              |
|----------------|-----------|-----------------|----------------------------|--------------------|
| Benzyl alcohol | Workers   | Inhalation      | Long-term systemic effects | 22 mg/m3           |
|                | Workers   | Inhalation      | Acute systemic effects     | 110 mg/m3          |
|                | Workers   | Skin contact    | Long-term systemic effects | 8 mg/kg<br>bw/day  |
|                | Workers   | Skin contact    | Acute systemic effects     | 40 mg/kg<br>bw/day |
|                | Consumers | Inhalation      | Long-term systemic effects | 5,4 mg/m3          |
|                | Consumers | Inhalation      | Acute systemic effects     | 27 mg/m3           |
|                | Consumers | Skin contact    | Long-term systemic effects | 4 mg/kg<br>bw/day  |
|                | Consumers | Skin contact    | Acute systemic effects     | 20 mg/kg<br>bw/day |
|                | Consumers | Ingestion       | Long-term systemic effects | 4 mg/kg<br>bw/day  |
|                | Consumers | Ingestion       | Acute systemic effects     | 20 mg/kg<br>bw/day |

## Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

| Substance name | Environmental Compartment | Value  |
|----------------|---------------------------|--------|
| Benzyl alcohol | Fresh water               | 1 mg/l |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

| II | Marine water             | 0,1 mg/l    |
|----|--------------------------|-------------|
|    | Intermittent use/release | 2,3 mg/l    |
|    | Sewage treatment plant   | 39 mg/l     |
|    | Fresh water sediment     | 5,27 mg/kg  |
|    | Marine sediment          | 0,527 mg/kg |
|    | Soil                     | 0,456 mg/kg |

## 8.2 Exposure controls

## **Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to NS EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

## **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : colourless

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.0 06.04.2024 1847031-00016 Date of first issue: 25.07.2017

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Flash point : > 93,3 °C

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

## **SECTION 10: Stability and reactivity**

## 10.1 Reactivity

Not classified as a reactivity hazard.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

#### 10.2 Chemical stability

Stable under normal conditions.

## 10.3 Possibility of hazardous reactions

Hazardous reactions : Vapours may form explosive mixture with air.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

#### **Components:**

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8.000 - 10.000 mg/kg

LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

administration)

LD50 (Rat): 67 - 96 mg/kg

**Application Route: Intravenous** 

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.0 06.04.2024 1847031-00016 Date of first issue: 25.07.2017

LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

Benzyl alcohol:

Acute oral toxicity : LD50 (Rat): 1.620 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 4,178 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

#### Skin corrosion/irritation

Not classified based on available information.

#### **Components:**

#### Gentamicin:

Species : Rabbit

Result : Mild skin irritation

#### Benzyl alcohol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

#### Gentamicin:

Species : Rabbit

Result : Mild eye irritation

#### Benzyl alcohol:

Species : Rabbit

Method : OECD Test Guideline 405

Result : Irritation to eyes, reversing within 21 days

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.0 06.04.2024 1847031-00016 Date of first issue: 25.07.2017

**Components:** 

Gentamicin:

Remarks : No data available

Benzyl alcohol:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

Benzyl alcohol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Carcinogenicity

Not classified based on available information.

**Components:** 

Gentamicin:

Carcinogenicity - Assess- : No data available

ment

Benzyl alcohol:

Species : Mouse

11/21

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

Application Route : Ingestion
Exposure time : 103 weeks

Method : OECD Test Guideline 451

Result : negative

#### Reproductive toxicity

May damage the unborn child.

#### **Components:**

#### Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3,6 mg/kg body weight

Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

#### Benzyl alcohol:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

: Test Type: Embryo-foetal development

Species: Mouse

Application Route: Ingestion

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.0 06.04.2024 1847031-00016 Date of first issue: 25.07.2017

Result: negative

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

#### Gentamicin:

Target Organs Kidney, inner ear

Assessment Causes damage to organs through prolonged or repeated

#### Repeated dose toxicity

#### **Components:**

#### Gentamicin:

Gentain
Species
LOAEL
Application Route
Exposure time
Target Organs Dog 3 mg/kg : Intramuscular : 12 Months : Kidney

Symptoms : Vomiting, Salivation

Species LOAEL Application Route Exposure time Target Organs : Monkey : 50 mg/kg : Subcutaneous : 3 Weeks

Target Organs Kidney, inner ear

LOAEL
Application Route
Exposure time
Target Organs Monkey 6 mg/kg Intramuscular 3 Weeks

Target Organs Blood, Kidney, inner ear, Liver

Rat Species NOAEL 5 mg/kg LOAEL 10 mg/kg Application Route
Exposure time
Target Organs Intramuscular 52 Weeks Target Organs : Kidney, Blood

Species : Rat NOAEL : 12,5 mg/kg : 50 mg/kg LOAEL Application Route : Intramuscular 13 Weeks Exposure time Target Organs Kidney

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

Benzyl alcohol:

Species : Rat

NOAEL : 1,072 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 28 Days

Method : OECD Test Guideline 412

**Aspiration toxicity** 

Not classified based on available information.

11.2 Information on other hazards

**Endocrine disrupting properties** 

**Product:** 

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

**Components:** 

Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

**SECTION 12: Ecological information** 

12.1 Toxicity

**Components:** 

Gentamicin:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1,5

μg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4,7 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1,6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

100

Toxicity to microorganisms : EC50 : 288,7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

M-Factor (Chronic aquatic

toxicity)

1

Benzyl alcohol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 460 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 230 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 770

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 310

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to daphnia and other : aguatic invertebrates (Chron-

ic toxicity)

NOEC: 51 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

#### 12.2 Persistence and degradability

## **Components:**

#### Gentamicin:

Biodegradability : Result: rapidly degradable

Biodegradation: 100 % Exposure time: 28 d

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.0 06.04.2024 1847031-00016 Date of first issue: 25.07.2017

Method: OECD Test Guideline 314

Benzyl alcohol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 92 - 96 %

Exposure time: 14 d

12.3 Bioaccumulative potential

**Components:** 

Gentamicin:

Partition coefficient: n-

octanol/water

: log Pow: < -2

Benzyl alcohol:

Partition coefficient: n-

octanol/water

: log Pow: 1,05

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

**Product:** 

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

**Product:** 

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

**SECTION 13: Disposal considerations** 

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.0 06.04.2024 1847031-00016 Date of first issue: 25.07.2017

If not otherwise specified: Dispose of as unused product.

## **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Gentamicin)

**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Gentamicin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Gentamicin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Gentamicin)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(Gentamicin)

## 14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

#### 14.4 Packing group

**ADN** 

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

**ADR** 

Packing group : III Classification Code : M6

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

Hazard Identification Number : 90 Labels : 9 Tunnel restriction code : (-)

**RID** 

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

**IMDG** 

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 964

ger aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

**ADN** 

Environmentally hazardous : yes

**ADR** 

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

**IMDG** 

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

# 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1847031-00016 Date of first issue: 25.07.2017 4.0

## **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

Conditions of restriction for the following entries should be considered: Number on list 75, 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

If you intend to use this product as tattoo ink, please contact your ven-

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de-

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

E1

Regulation (EU) No 649/2012 of the European Parlia-

ment and the Council concerning the export and import of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

**ENVIRONMENTAL** 100 t 200 t

**HAZARDS** 

#### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

**AICS** not determined

DSL not determined

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Gentamicin (8%) Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H332 : Harmful if inhaled.

H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergencv Schedule: ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Gentamicin (8%) Injection Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.0
 06.04.2024
 1847031-00016
 Date of first issue: 25.07.2017

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Repr. 1A

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 2

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Classification procedure:

cy, http://echa.europa.eu/

#### Classification of the mixture:

# H360D Calculation method H373 Calculation method H400 Calculation method H411 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN